-
Innovation Ranking
NewInnovation Ranking – UCB SA
UCB SA (UCB) is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company's marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UCB-0022 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UCB-0022 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UCB-0022 in Parkinson's Disease Drug Details: UCB-0022 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UCB-8600 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UCB-8600 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UCB-8600 in Atopic Dermatitis (Atopic Eczema) Drug Details: UCB-8600 is...
-
Product Insights
NewNet Present Value Model: UCB SA’s Alprazolam
Empower your strategies with our Net Present Value Model: UCB SA's Alprazolam report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: UCB SA’s Rozanolixizumab
Empower your strategies with our Net Present Value Model: UCB SA's Rozanolixizumab report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of UCB SA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of UCB SA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UCB-7853 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UCB-7853 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.UCB-7853 in Parkinson's DiseaseDrug Details:UCB-7853 is under development for the treatment of Parkinson's...
-
Product Insights
NewNet Present Value Model: Seelos Therapeutics, Inc.’s Ketamine Hydrochloride
Empower your strategies with our Net Present Value Model: Seelos Therapeutics, Inc.'s Ketamine Hydrochloride report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Bimekizumab in Axial Spondyloarthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bimekizumab in Axial Spondyloarthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bimekizumab in Axial Spondyloarthritis Drug Details: Bimekizumab (Bimzelx) is a humanised IgG1monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UCB-1381 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UCB-1381 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.UCB-1381 in Atopic Dermatitis (Atopic Eczema) Drug Details:UCB-1381 is under development...